Bristol-Myers Squibb Company
Methods for treating costimulation blockade resistant rejection

Last updated:

Abstract:

The present invention provides methods utilizing changes in CD4+CD57+ T cells levels for determining the susceptibility of a transplant patient or patient in need thereof to costimulation blockade resistant rejection. These methods are useful for identifying effective drug regimens for the treatment of immune disorders associated with graft transplantation and/or maintenance of a transplant.

Status:
Grant
Type:

Utility

Filling date:

23 Oct 2019

Issue date:

12 Jul 2022